Article Sidebar

Download
View Article
Statistic
Read Counter : 10 Download : 8

Main Article Content

Abstract

Background: The COVID-19 pandemic, instigated by the SARS-CoV-2 virus, has precipitated unprecedented global health and economic challenges since its identification in late 2019. Specific Background: To date, over 770 million confirmed COVID-19 cases and millions of deaths have been documented worldwide. Individuals with Type 2 Diabetes Mellitus (T2DM) are particularly vulnerable, exhibiting an elevated risk of severe illness and mortality due to exacerbated inflammatory responses and frequent comorbidities such as cardiovascular disease, hypertension, and obesity. Knowledge Gap: Despite the known risks, the precise molecular interactions between SARS-CoV-2 and host cells, and how these may be modified by diabetes and its comorbidities, remain inadequately understood. Aims: This study aims to elucidate the molecular mechanisms underpinning the interaction between SARS-CoV-2 and human cells, with a specific focus on how T2DM influences these interactions. Results: Preliminary findings indicate that the presence of T2DM amplifies the inflammatory response to SARS-CoV-2 infection, likely through altered receptor interactions and exacerbated immune responses. Novelty: This research provides new insights into the differential impact of SARS-CoV-2 on diabetic versus non-diabetic patients, highlighting the role of diabetes-induced alterations in viral pathogenesis. Implications: Understanding these mechanisms is crucial for developing targeted therapeutic and preventive strategies to mitigate the heightened risk faced by individuals with T2DM during pandemics, thereby informing public health policies and clinical practices.

Keywords

SARS-CoV-2 Type 2 diabetes mellitus (T2DM) Cytokine storm Cardiovascular complications Glycemic control

Article Details

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite
D.K, N., A, U. D., G, S. N., & A, P. S. (2024). IMPACT OF COVID-19 ON CARDIOVASCULAR COMPLICATIONS IN TYPE 2 DIABETES. Journal of Medical Genetics and Clinical Biology, 1(8), 351–354. https://doi.org/10.61796/jmgcb.v1i8.889
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. Сабиров, М., Бобокулов, М., Хайитов, Х., & Мунавваров, Б. (2022). БУЙРАК ТРАНСПЛАНТАЦИЯСИ: ТИББИЙ ҲАМДА ИЖТИМОИЙ МУАММОЛАРИ ВА УЛАРГА КЛИНИК ЁНДАШУВ. Журнал" Медицина и инновации", (3), 111-120.
  2. Зарипов, С. И., Тураев, И. А., & Рахимов, С. С. (2022). Quality of life in patients with chronic kidney disease receiving program hemodialysis and possible ways of its correction. УЗБЕКСКИЙ МЕДИЦИНСКИЙ ЖУРНАЛ, 3(5).
  3. Istamovich, Z. S., Sadullayevich, A. K., & Mirza-Bakhtiyarkhanovna, A. N. (2023). THE SIGNIFICANCE OF AUTOANTIBODIES IN THE PATHOGENESIS OF SYSTEMIC SCLEROSIS (LITERATURE REVIEW). JOURNAL OF BIOMEDICINE AND PRACTICE, 8(2).
  4. Rakhimova, M. B., Akhmedov, K. S., Rakhimov, S. S., & Zaripov, S. I. (2023). Extrasceletal Manifestations in Patients with Ankylosing Spondylitis. Journal of Coastal Life Medicine, 11, 1315-1321.
  5. SI, Z., & Raximova, M. B. (2023). QUALITY OF LIFE IN PATIENTS WITH TERMINAL STAGE RENAL DISEASE RECEIVING PROGRAMMED HEMODIALYSIS. INNOVATION IN THE MODERN EDUCATION SYSTEM, 3(26), 228-229.
  6. Umarova, Z. F., Jumanazarov, S. B., Zaripov, S. I., & Khaydarov, R. M. (2024). QUALITY OF LIFE IN PATIENTS WITH CHRONIC KIDNEY DISEASE IN THE V STAGE RECEIVING PROGRAM HEMODIALYSIS AND POSSIBLE WAYS OF ITS CORRECTION.
  7. Zaripov, S. I., & Abdurakhmanova, N. M. B. (2024). The relationship between systemic sclerosis and anti-fibrillarin antibodies. Journal of Modern Educational Achievements, 6(6), 235-238.
  8. Zaripov, S. I., & Abdurakhmanova, N. M. (2023). Quality of life of End-Stage Renal Disease (ESRD) patients receiving hemodialysis: influencing factors and approaches to correction. Texas Journal of Multidisciplinary Studies, 21, 14-17.